company background image

BeiGene NasdaqGS:BGNE Stock Report

Last Price


Market Cap







07 Aug, 2022


Company Financials +
BGNE fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health5/6

BGNE Stock Overview

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide.

BeiGene Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BeiGene
Historical stock prices
Current Share PriceUS$194.47
52 Week HighUS$426.56
52 Week LowUS$118.18
1 Month Change3.04%
3 Month Change44.89%
1 Year Change-39.50%
3 Year Change46.24%
5 Year Change173.82%
Change since IPO586.69%

Recent News & Updates

Jul 14

FDA defers action on Novartis/BeiGene's tislelizumab for esophagus cancer citing inspection woes

The U.S. Food and Drug Administration (FDA) deferred action on approving BeiGene (NASDAQ:BGNE) and Novartis' (NYSE:NVS) tislelizumab for esophageal cancer as the agency was unable to carry out required inspections in China due to COVID-19 related travel restrictions. BeiGene's biologics license application (BLA) was seeking approval of tislelizumab as a second-line (2L) therapy for patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC). The FDA was expected to take a decision by July 12, after accepting the BLA in September 2021. BeiGene (BGNE) said the FDA was deferring action on the application until the inspections are complete and did not not provide a new expected action date. The BLA remains under review. "We are working with our partner, Novartis, to facilitate the required inspections and bring tislelizumab to patients with second-line esophageal cancer in the U.S. following regulatory approval," said BeiGene's Co-Founder, Chairman and CEO John Oyler. The BLA was backed by data from a phase 3 trial called RATIONALE 302.

Jul 06

BeiGene in pact with InnoRNA to develop messenger RNA-based therapies

Chinese biotechnology company, BeiGene (NASDAQ:BGNE) announced Wednesday an agreement to develop messenger RNA-based therapies in partnership with InnoRNA, a biotech with expertise in LNP-based delivery technology and mRNA drug discovery. Per the terms of the collaboration, the two companies will jointly develop multiple mRNA-LNP programs. BeiGene (BGNE) will have the exclusive global rights for the development and commercialization of the product candidates jointly discovered by the two companies. In return, InnoRNA will receive an upfront cash payment in addition to tiered royalties and milestone payments based on certain development, regulatory, and commercial events. The company will also receive a non-exclusive license to InnoRNA’s proprietary LNP Technology in exchange for an additional upfront cash payment and milestone payments to InnoRNA. Read: In June, Citi argued BeiGene (BGNE) could benefit as China eases COVID-driven travel restrictions.

Shareholder Returns

BGNEUS BiotechsUS Market

Return vs Industry: BGNE underperformed the US Biotechs industry which returned -24.5% over the past year.

Return vs Market: BGNE underperformed the US Market which returned -12.9% over the past year.

Price Volatility

Is BGNE's price volatile compared to industry and market?
BGNE volatility
BGNE Average Weekly Movement13.3%
Biotechs Industry Average Movement12.9%
Market Average Movement7.9%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: BGNE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: BGNE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

20108,500John Oyler

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors.

BeiGene Fundamentals Summary

How do BeiGene's earnings and revenue compare to its market cap?
BGNE fundamental statistics
Market CapUS$20.12b
Earnings (TTM)-US$2.01b
Revenue (TTM)US$1.07b


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BGNE income statement (TTM)
Cost of RevenueUS$1.78b
Gross Profit-US$714.29m
Other ExpensesUS$1.29b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-19.38
Gross Margin-66.84%
Net Profit Margin-187.65%
Debt/Equity Ratio10.7%

How did BGNE perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is BGNE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BGNE?

Other financial metrics that can be useful for relative valuation.

BGNE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue14x
Enterprise Value/EBITDA-8.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BGNE's PS Ratio compare to its peers?

BGNE PS Ratio vs Peers
The above table shows the PS ratio for BGNE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average14.2x
HZNP Horizon Therapeutics
ALNY Alnylam Pharmaceuticals
SGEN Seagen
INCY Incyte
BGNE BeiGene

Price-To-Sales vs Peers: BGNE is expensive based on its Price-To-Sales Ratio (18.8x) compared to the peer average (14.2x).

Price to Earnings Ratio vs Industry

How does BGNE's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: BGNE is expensive based on its Price-To-Sales Ratio (18.8x) compared to the US Biotechs industry average (16.6x)

Price to Sales Ratio vs Fair Ratio

What is BGNE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BGNE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio18.8x
Fair PS Ratio5.4x

Price-To-Sales vs Fair Ratio: BGNE is expensive based on its Price-To-Sales Ratio (18.8x) compared to the estimated Fair Price-To-Sales Ratio (5.4x).

Share Price vs Fair Value

What is the Fair Price of BGNE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BGNE ($194.47) is trading below our estimate of fair value ($1407.42)

Significantly Below Fair Value: BGNE is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Future Growth

How is BeiGene forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?

Future Growth Score


Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BGNE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BGNE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BGNE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BGNE's revenue (30.7% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: BGNE's revenue (30.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BGNE is forecast to be unprofitable in 3 years.

Discover growth companies

Past Performance

How has BeiGene performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BGNE is currently unprofitable.

Growing Profit Margin: BGNE is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: BGNE is unprofitable, and losses have increased over the past 5 years at a rate of 39.2% per year.

Accelerating Growth: Unable to compare BGNE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BGNE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.8%).

Return on Equity

High ROE: BGNE has a negative Return on Equity (-37.82%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is BeiGene's financial position?

Financial Health Score


Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BGNE's short term assets ($5.9B) exceed its short term liabilities ($1.0B).

Long Term Liabilities: BGNE's short term assets ($5.9B) exceed its long term liabilities ($1.0B).

Debt to Equity History and Analysis

Debt Level: BGNE has more cash than its total debt.

Reducing Debt: BGNE's debt to equity ratio has reduced from 55.4% to 10.7% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BGNE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if BGNE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies


What is BeiGene current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BGNE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BGNE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BGNE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BGNE's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BGNE has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


John Oyler (54 yo)





Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....

CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD16.75M) is about average for companies of similar size in the US market ($USD12.96M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: BGNE's management team is considered experienced (4.7 years average tenure).

Board Members

Experienced Board: BGNE's board of directors are considered experienced (6.5 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: BGNE insiders have only sold shares in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.6%.

Top Shareholders

Company Information

BeiGene, Ltd.'s employee growth, exchange listings and data sources

Key Information

  • Name: BeiGene, Ltd.
  • Ticker: BGNE
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$20.122b
  • Shares outstanding: 103.47m
  • Website:

Number of Employees


  • BeiGene, Ltd.
  • 55 Cambridge Parkway
  • Suite 700W
  • Cambridge
  • Massachusetts
  • 2142
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/07 00:00
End of Day Share Price2022/08/05 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.